Strategic management paper for Boehriger Ingelheim Philippines
2006
- 75Usage
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Usage75
- Abstract Views75
Interview Description
Boehringer Ingelheim Philippines is a wholly-owned subsidiary of Boehringer Ingelheim International GmBH, with headquarters in the city of Ingelheim am Rhein, Germany. Boehringer Ingelheim Philippines belongs to the Australasia sectionBoehringer Ingelheim Phil, Inc. (BIPHI) is one of the leading pharmaceutical companies in the Philippines. It markets human and animal health products (prescription medicines, consumer health products and animal vaccines) that are known for their quality and efficacy. The human pharmaceuticals business accounts for 95 percent (70.2% Prescription Medicines and 24.8% CHC) of the company's total revenue while the animal health division accounts for only 5%. The product line of Boehringer Ingelheim, (Phil.) Inc. is composed of cardiovascular, respiratory and neurological medicines.Boehringer Ingelheim, Phils. is divided into three divisions the Prescription Medicines Division, Consumer Health Care Division and the Animal Health Division. The Consumer Health Care Division markets OTC (over-the-counter) drugs such as Pharmaton, Dulcolax, Kiddi Pharmaton, and Bisolvon.The Prescription Medicines Division (Ethical) presently markets drugs such as Mucosolvan, Spiriva, Micardis, Micardis Plus, Sifrol, Mobic, Primavent, Persantin, Berodual, Combivent UDV, Aggrenox and Buscopan.The Animal Health Division markets animal vaccines such as Ingelvac, Enterisol, Reprocycle, Volvac and Bar Somnus.
Bibliographic Details
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know